| Peripheral T-cell Lymphoma |
NCT03952572: Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Cyclophosphamide, CTX, pegylated liposomal doxorubicin, PLD, Vincristine, VCR, Prednisone, PED, Doxorubicin, DOX | Peking University | Peripheral T-cell Lymphoma | 04/23 | 04/23 | | |
NCT05075460: Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 3 | 107 | RoW | Tucidinostat, Azacitidine combined with CHOP | Peking Union Medical College Hospital | T-cell Lymphoma | 05/24 | 10/24 | | |
| Not yet recruiting | 3 | 20 | NA | Brentuximab vedotin, 89ZR-Brentuximab | University Medical Center Groningen, Takeda | Diffuse Large B-cell-lymphoma | 01/25 | 01/26 | | |
NCT06561048: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma |
|
|
| Not yet recruiting | 3 | 150 | NA | Soquelitinib, CPI-818, Belinostat, Beleodaq®, Pralatrexate, Folotyn® | Corvus Pharmaceuticals, Inc. | Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell | 02/26 | 09/27 | | |
NCT04880746: Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study |
|
|
| Recruiting | 3 | 266 | RoW | BEAC, Cladribine combined with BEAC | Ruijin Hospital, Xinqiao Hospital of Chongqing, The First Affiliated Hospital of Anhui Medical University, Harbin Hematology and Oncology Institute, The Affiliated Zhongshan Hospital of Dalian University, Qilu Hospital of Shandong University, Fujian Medical University Union Hospital, Shanxi Province Cancer Hospital, RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Huashan Hospital | Peripheral T-cell Lymphoma | 10/24 | 10/25 | | |
NCT05931263: A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL |
|
|
| Recruiting | 3 | 104 | RoW | C-BEAM Regimen, BEAM Regimen | The First Affiliated Hospital with Nanjing Medical University | Newly Diagnosed Peripheral T-cell Lymphoma | 02/26 | 02/28 | | |
NCT06122389: SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide | Jiangsu HengRui Medicine Co., Ltd. | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | 05/26 | 07/26 | | |
TOTEM-01, NCT05205902: TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides |
|
|
| Not yet recruiting | 3 | 78 | NA | Low-dose total-skin electron-beam therapy, Phototherapy | Assistance Publique - Hôpitaux de Paris | Mycosis Fungoides, Cutaneous T Cell Lymphoma | 02/27 | 02/31 | | |
NCT05678933: AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH |
|
|
| Enrolling by invitation | 3 | 200 | RoW | Azacitidine, Chidamide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Tianjin Medical University Cancer Institute and Hospital | Peripheral T-cell Lymphoma Targeted Therapy | 12/27 | 12/29 | | |
NCT04668690: Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL |
|
|
| Not yet recruiting | 3 | 190 | RoW | Mitoxantrone Hydrochloride Liposome Injection, HE071, Liposomal Mitoxantrone Hydrochloride Injection, Chidamide | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Peripheral T Cell Lymphoma | 12/27 | 12/28 | | |
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL |
|
|
| Recruiting | 3 | 504 | US, RoW | Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone | Acrotech Biopharma Inc. | Peripheral T Cell Lymphoma | 07/30 | 11/30 | | |
2010-021091-28: A clinical study to determine whether a new drug masitinib is safe and effective in cancer of the white blood cells. |
|
|
| Ongoing | 2/3 | 267 | Europe, RoW | Masitinib mesylate, Gemcitabine, Dexamethasone, AB1010, Film-coated tablet, Powder for infusion, Tablet, Gemcitabine, Dexamethasone | AB Science, AB Science | Relapsed or refractory peripheral T-cell lymphoma, Cancer of the white blood cells (T-lymphocytes), Diseases [C] - Cancer [C04] | | | | |
NCT06548347: A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma |
|
|
| Not yet recruiting | 2/3 | 606 | NA | Linperlisib, CHOP | Shanghai YingLi Pharmaceutical Co. Ltd. | Peripheral T Cell Lymphoma | 12/24 | 09/29 | | |
NCT05822050: An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL |
|
|
| Recruiting | 2/3 | 20 | RoW | Selinexor | The First Hospital of Jilin University | PTCL Patients Who Achieved Complete Response From Frontline Treatment | 12/24 | 06/25 | | |
